Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2023-04-20 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
申万宏源证券承销保荐有限责任公司关于北京三元基因药业股份有限公司2022年度募集资金存放与实际使用情况的专项核查报告
Regulatory Filings
2023-04-20 Chinese
独立董事关于第三届董事会第八次会议相关事项的独立意见公告
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on several board meeting agenda items, including profit distribution, fundraising usage, auditor appointment, and management appointment. It references the 2022 fiscal year and audit reports but does not contain full financial statements or detailed financial data. It is a governance-related document expressing independent directors' views on board decisions and proposals to be submitted to shareholders. The document length is short (1798 characters), and it is not a full annual report or audit report but rather a board/management information announcement related to governance and management changes. Therefore, the most appropriate classification is Board/Management Information (MANG).
2023-04-20 Chinese
第三届监事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the meeting held on April 19, 2023, including the approval of the 2022 Supervisory Board Work Report, the 2022 Annual Report and its summary, the 2022 Financial Final Accounts Report, the 2022 Profit Distribution Plan, the 2023 Financial Budget Report, and other related financial and supervisory matters. The document is a formal announcement of meeting resolutions and approvals, not the full annual report itself. It also states that these matters will be submitted to the shareholders' meeting for further approval. The document length is 2535 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of supervisory board meeting resolutions related to the annual report and financial matters, but it does not contain the full annual report or detailed financial statements itself.
2023-04-20 Chinese
募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the company's fundraising activities, specifically focusing on the storage and actual use of raised funds during the 2022 fiscal year. It references regulatory guidelines related to fundraising management and includes audited financial figures, usage progress, and compliance statements from auditors and sponsors. The content is consistent with a specialized report on capital raising and fund usage rather than a general financial report or announcement. The presence of detailed financial data and audit opinions confirms it is a substantive report rather than a brief announcement or certification. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2023-04-20 Chinese
关于召开2022年年度股东大会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a notice announcing the convening of the 2022 Annual General Meeting (AGM) of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It includes details about the meeting date, voting methods (onsite and online), agenda items to be discussed (such as the 2022 annual report, board and supervisory reports, profit distribution plan, and auditor reappointment), and registration procedures. The document does not contain the actual reports or financial statements but refers to them being disclosed elsewhere (on the Beijing Stock Exchange website). The document length is 3680 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as AGM Information (AGM-R).
2023-04-20 Chinese
2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as an "年度报告摘要" which translates to "Annual Report Summary" for the year 2022. It contains detailed company information including business overview, financial data for multiple years, shareholder structure, and important operational matters. The presence of audited financial data, management assurances, and comprehensive business descriptions aligns with the characteristics of an Annual Report (10-K equivalent). The document length is 9604 characters, which is substantial and contains actual financial data and analysis, not just an announcement or summary. Therefore, it is classified as an Annual Report (10-K). FY 2022
2023-04-20 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.